NCT05567471View on ClinicalTrials.gov

Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose

PHASE3CompletedINTERVENTIONAL
Enrollment

875

Participants

Timeline

Start Date

February 26, 2022

Primary Completion Date

May 3, 2022

Study Completion Date

September 28, 2022

Conditions
COVID-19 Respiratory Infection
Interventions
BIOLOGICAL

BBV154 Intranasal Vaccine

Administered BBV154 vaccine in form of drops (0.5 mL) via intranasal route

BIOLOGICAL

Intramuscular vaccine COVAXIN

Administered BBV152 vaccine via intramuscular route

BIOLOGICAL

Covishield

Administered vaccine via intramuscular route

Trial Locations (9)

110029

AIIMS, New Delhi, New Delhi

121001

ESIC Medical College and Hospital, Faridabad

208002

Prakhar Hospital Pvt Ltd, Kanpur

273001

Rana Hospital Pvt Ltd, Gorakhpur

440009

Gillurkar Multispeciality Hopistal, Nagpur

500018

St. Theresa Hospital, Hyderabad

560003

Vagus Super Specilaity Hospitals, Bangalore

590002

Jeevan Rekha Hospital, Belagavi

801507

All India Institute of Medical Sciences, Patna

All Listed Sponsors
lead

Bharat Biotech International Limited

INDUSTRY